A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women

Detalhes bibliográficos
Autor(a) principal: Joura, E. A.
Data de Publicação: 2015
Outros Autores: Giuliano, Anna R., Iversen, O. E., Bouchard, C., Mao, C., Mehlsen, J., Moreira Júnior, Edson Duarte, Ngan, Y., Petersen, L. K., Lazcano‑Ponce, E., Pitisuttithum, P., Restrepo, J. A., Stuart, G., Woelber, L., Yang, Y. C., Cuzick, J., Garland, S. M., Huh, W., Kjaer, S. K., Bautista, Oliver M., Chan, I. S. F., Chen, J., Gesser, R., Moeller, E., Ritter, M., Vuocolo, S., Luxembourg, A., Broad Spectrum HPV Vaccine Study
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/13256
Resumo: The Medical University of Vienna. Comprehensive Cancer Center. Vienna.
id CRUZ_6dd8c3de068ff747654577e3b6f8e019
oai_identifier_str oai:www.arca.fiocruz.br:icict/13256
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Joura, E. A.Giuliano, Anna R.Iversen, O. E.Bouchard, C.Mao, C.Mehlsen, J.Moreira Júnior, Edson DuarteNgan, Y.Petersen, L. K.Lazcano‑Ponce, E.Pitisuttithum, P.Restrepo, J. A.Stuart, G.Woelber, L.Yang, Y. C.Cuzick, J.Garland, S. M.Huh, W.Kjaer, S. K.Bautista, Oliver M.Chan, I. S. F.Chen, J.Gesser, R.Moeller, E.Ritter, M.Vuocolo, S.Luxembourg, A.Broad Spectrum HPV Vaccine Study2016-03-23T18:18:32Z2016-03-23T18:18:32Z2015JOURA, E. A. et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, v. 372, n. 8, p. 711-723, 2015.1533-4406https://www.arca.fiocruz.br/handle/icict/1325610.1056/NEJMoa1405044engMassachusetts Medical SocietyA 9-valent HPV vaccine against infection and intraepithelial neoplasia in womeninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleThe Medical University of Vienna. Comprehensive Cancer Center. Vienna.Moffitt Cancer Center. Tampa, Florida, USA.University of Bergen–Haukeland University Hospital. Department of Clinical Medicine. Bergen, Norway.Université Laval. Québec, Canadá.University of Washington. Seattle, USA.University of Copenhagen. Coordinating Research Center. Frederiksberg Hospital. Copenhagen.Associação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.University of Hong Kong. Hong Kong.Aarhus University Hospital. Department of Obstetrics and Gynecology. Aarhus, Denmark.Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.Mahidol University. Faculty of Tropical Medicine. Nakhon Pathom, Thailand.Investigación Clínica. Medellín, Colombia.University of British Columbia. Vancouver, Canada.University Medical Center Hamburg–Eppendorf. Department of Gynecology. Hamburg, Germany.Mackay Memorial Hospital. Taipei, Taiwan.Wolfson Institute of Preventive Medicine. London.Royal Women’s Hospital. University of Melbourne and Murdoch Childrens Research Institute. Parkville, VIC, Australia.University of Alabama. Division of Gynecologic Oncology. Birmingham.Danish Cancer Society Research Center and Department of Gynecology. Rigshospitalet, Copenhagen.University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.University of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJUniversity of Alabama. Division of Gynecologic Oncology. Birmingham / Merck, Whitehouse Station, NJ, USA.Broad Spectrum HPV Vaccine Study.BACKGROUND: The investigational 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and five additional oncogenic types (31, 33, 45, 52, and 58). Here we present the results of a study of the efficacy and immunogenicity of the 9vHPV vaccine in women 16 to 26 years of age. METHODS: We performed a randomized, international, double-blind, phase 2b-3 study of the 9vHPV vaccine in 14,215 women. Participants received the 9vHPV vaccine or the qHPV vaccine in a series of three intramuscular injections on day 1 and at months 2 and 6. Serum was collected for analysis of antibody responses. Swabs of labial, vulvar, perineal, perianal, endocervical, and ectocervical tissue were obtained and used for HPV DNA testing, and liquid-based cytologic testing (Papanicolaou testing) was performed regularly. Tissue obtained by means of biopsy or as part of definitive therapy (including a loop electrosurgical excision procedure and conization) was tested for HPV. RESULTS: The rate of high-grade cervical, vulvar, or vaginal disease irrespective of HPV type (i.e., disease caused by HPV types included in the 9vHPV vaccine and those not included) in the modified intention-to-treat population (which included participants with and those without prevalent infection or disease) was 14.0 per 1000 person-years in both vaccine groups. The rate of high-grade cervical, vulvar, or vaginal disease related to HPV-31, 33, 45, 52, and 58 in a prespecified per-protocol efficacy population (susceptible population) was 0.1 per 1000 person-years in the 9vHPV group and 1.6 per 1000 person-years in the qHPV group (efficacy of the 9vHPV vaccine, 96.7%; 95% confidence interval, 80.9 to 99.8). Antibody responses to HPV-6, 11, 16, and 18 were noninferior to those generated by the qHPV vaccine. Adverse events related to injection site were more common in the 9vHPV group than in the qHPV group. CONCLUSIONS: The 9vHPV vaccine prevented infection and disease related to HPV-31, 33, 45, 52, and 58 in a susceptible population and generated an antibody response to HPV-6, 11, 16, and 18 that was noninferior to that generated by the qHPV vaccine. The 9vHPV vaccine did not prevent infection and disease related to HPV types beyond the nine types covered by the vaccine.9-Valent HPV VaccineInfection NeoplasiaIntraepithelial NeoplasiaWomenAlphapapillomavirusNeoplasia Intraepitelial Cervical/prevenção & controleInfecções por Papillomavirus/prevenção & controleVacinas contra PapillomavirusNeoplasias do Colo do Útero/prevenção & controleAdolescenteAdultoAnticorpos Antivirais/sangueNeoplasia Intraepitelial Cervical/virologiaMétodo Duplo-CegoFemininoDoenças dos Genitais Femininos/epidemiologiaHumanosIncidênciaAnálise de Intenção de TratamentoInfecções por Papillomavirus/epidemiologiaVacinas contra Papillomavirus/administração & dosagemNeoplasias do Colo do Útero/virologiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/13256/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALJoura EA A 9-valent....pdfJoura EA A 9-valent....pdfapplication/pdf459983https://www.arca.fiocruz.br/bitstream/icict/13256/2/Joura%20EA%20A%209-valent....pdfe7a12c9084a672048403e87b557da624MD52TEXTJoura EA A 9-valent....pdf.txtJoura EA A 9-valent....pdf.txtExtracted texttext/plain61585https://www.arca.fiocruz.br/bitstream/icict/13256/3/Joura%20EA%20A%209-valent....pdf.txt8e2680c64899587291dcfb933399b430MD53icict/132562023-03-15 14:34:01.874oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:01Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
title A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
spellingShingle A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A.
9-Valent HPV Vaccine
Infection Neoplasia
Intraepithelial Neoplasia
Women
Alphapapillomavirus
Neoplasia Intraepitelial Cervical/prevenção & controle
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus
Neoplasias do Colo do Útero/prevenção & controle
Adolescente
Adulto
Anticorpos Antivirais/sangue
Neoplasia Intraepitelial Cervical/virologia
Método Duplo-Cego
Feminino
Doenças dos Genitais Femininos/epidemiologia
Humanos
Incidência
Análise de Intenção de Tratamento
Infecções por Papillomavirus/epidemiologia
Vacinas contra Papillomavirus/administração & dosagem
Neoplasias do Colo do Útero/virologia
title_short A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
title_full A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
title_fullStr A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
title_full_unstemmed A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
title_sort A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
author Joura, E. A.
author_facet Joura, E. A.
Giuliano, Anna R.
Iversen, O. E.
Bouchard, C.
Mao, C.
Mehlsen, J.
Moreira Júnior, Edson Duarte
Ngan, Y.
Petersen, L. K.
Lazcano‑Ponce, E.
Pitisuttithum, P.
Restrepo, J. A.
Stuart, G.
Woelber, L.
Yang, Y. C.
Cuzick, J.
Garland, S. M.
Huh, W.
Kjaer, S. K.
Bautista, Oliver M.
Chan, I. S. F.
Chen, J.
Gesser, R.
Moeller, E.
Ritter, M.
Vuocolo, S.
Luxembourg, A.
Broad Spectrum HPV Vaccine Study
author_role author
author2 Giuliano, Anna R.
Iversen, O. E.
Bouchard, C.
Mao, C.
Mehlsen, J.
Moreira Júnior, Edson Duarte
Ngan, Y.
Petersen, L. K.
Lazcano‑Ponce, E.
Pitisuttithum, P.
Restrepo, J. A.
Stuart, G.
Woelber, L.
Yang, Y. C.
Cuzick, J.
Garland, S. M.
Huh, W.
Kjaer, S. K.
Bautista, Oliver M.
Chan, I. S. F.
Chen, J.
Gesser, R.
Moeller, E.
Ritter, M.
Vuocolo, S.
Luxembourg, A.
Broad Spectrum HPV Vaccine Study
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Joura, E. A.
Giuliano, Anna R.
Iversen, O. E.
Bouchard, C.
Mao, C.
Mehlsen, J.
Moreira Júnior, Edson Duarte
Ngan, Y.
Petersen, L. K.
Lazcano‑Ponce, E.
Pitisuttithum, P.
Restrepo, J. A.
Stuart, G.
Woelber, L.
Yang, Y. C.
Cuzick, J.
Garland, S. M.
Huh, W.
Kjaer, S. K.
Bautista, Oliver M.
Chan, I. S. F.
Chen, J.
Gesser, R.
Moeller, E.
Ritter, M.
Vuocolo, S.
Luxembourg, A.
Broad Spectrum HPV Vaccine Study
dc.subject.en.pt_BR.fl_str_mv 9-Valent HPV Vaccine
Infection Neoplasia
Intraepithelial Neoplasia
Women
topic 9-Valent HPV Vaccine
Infection Neoplasia
Intraepithelial Neoplasia
Women
Alphapapillomavirus
Neoplasia Intraepitelial Cervical/prevenção & controle
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus
Neoplasias do Colo do Útero/prevenção & controle
Adolescente
Adulto
Anticorpos Antivirais/sangue
Neoplasia Intraepitelial Cervical/virologia
Método Duplo-Cego
Feminino
Doenças dos Genitais Femininos/epidemiologia
Humanos
Incidência
Análise de Intenção de Tratamento
Infecções por Papillomavirus/epidemiologia
Vacinas contra Papillomavirus/administração & dosagem
Neoplasias do Colo do Útero/virologia
dc.subject.decs.pt_BR.fl_str_mv Alphapapillomavirus
Neoplasia Intraepitelial Cervical/prevenção & controle
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus
Neoplasias do Colo do Útero/prevenção & controle
Adolescente
Adulto
Anticorpos Antivirais/sangue
Neoplasia Intraepitelial Cervical/virologia
Método Duplo-Cego
Feminino
Doenças dos Genitais Femininos/epidemiologia
Humanos
Incidência
Análise de Intenção de Tratamento
Infecções por Papillomavirus/epidemiologia
Vacinas contra Papillomavirus/administração & dosagem
Neoplasias do Colo do Útero/virologia
description The Medical University of Vienna. Comprehensive Cancer Center. Vienna.
publishDate 2015
dc.date.issued.fl_str_mv 2015
dc.date.accessioned.fl_str_mv 2016-03-23T18:18:32Z
dc.date.available.fl_str_mv 2016-03-23T18:18:32Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv JOURA, E. A. et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, v. 372, n. 8, p. 711-723, 2015.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/13256
dc.identifier.issn.none.fl_str_mv 1533-4406
dc.identifier.doi.pt_BR.fl_str_mv 10.1056/NEJMoa1405044
identifier_str_mv JOURA, E. A. et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, v. 372, n. 8, p. 711-723, 2015.
1533-4406
10.1056/NEJMoa1405044
url https://www.arca.fiocruz.br/handle/icict/13256
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Massachusetts Medical Society
publisher.none.fl_str_mv Massachusetts Medical Society
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/13256/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/13256/2/Joura%20EA%20A%209-valent....pdf
https://www.arca.fiocruz.br/bitstream/icict/13256/3/Joura%20EA%20A%209-valent....pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
e7a12c9084a672048403e87b557da624
8e2680c64899587291dcfb933399b430
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1794075750205227008